Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff, Carel W. le Roux, Adam Stefański, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 10
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition
Fabian Stoll, Tobias Kantowski, Jonas Laaser, et al.
Obesity Research & Clinical Practice (2025) Vol. 19, Iss. 1, pp. 63-69
Open Access | Times Cited: 3
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 2
Pre-Type 1 Diabetes in Adolescents and Teens: Screening, Nutritional Interventions, Beta-Cell Preservation, and Psychosocial Impacts
Brody Sundheim, Krish Hirani, M Blaschke, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 383-383
Open Access | Times Cited: 1
Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretionin vitroandin vivoof a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001
Yusman Manchanda, Ben Jones, Gaëlle Carrat, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Prediabetes remission to reduce the global burden of type 2 diabetes
Leontine Sandforth, Stephanie Kullmann, Arvid Sandforth, et al.
Trends in Endocrinology and Metabolism (2025)
Open Access | Times Cited: 1
Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Nikolaos Theodorakis, Maria Nikolaou, Andrew J. Krentz
Biomolecules (2025) Vol. 15, Iss. 3, pp. 373-373
Open Access | Times Cited: 1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Allison B. Reiss, Shelly Gulkarov, Raymond Lau, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 408-408
Open Access | Times Cited: 1
Diabetes, obesity, and cardiovascular disease—what is the impact of lifestyle modification?
Celina Seth, Veronika Schmid, Stephan Mueller, et al.
Herz (2025)
Closed Access | Times Cited: 1
Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease
Yujian Li, Dun Li, Jing Lin, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Andrijana Kirsch, Juergen Gindlhuber, Diana Zabini, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 11
Open Access
Mémoire adipocytaire de l’obésité et rechute pondérale : la réponse n’est-elle pas la prévention plutôt que les médicaments ?
Serge Halimi
Médecine des Maladies Métaboliques (2025)
Closed Access
Real-World Efficacy of Tirzepatide in Patients with Heart Failure without Diabetes
Silvio Nunes Augusto, David C. Kaelber, W.H. Wilson Tang
Current Problems in Cardiology (2025), pp. 102998-102998
Open Access
Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
Katharine Lang
BMJ (2025), pp. q2636-q2636
Closed Access
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Stuart W. Flint, Verónica Vázquez‐Velázquez, Sarah Le Brocq, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Taxifolin as a Therapeutic Potential for Weight Loss: A Retrospective Longitudinal Study
Yorito Hattori, Yuriko Nakaoku, Soshiro Ogata, et al.
Nutrients (2025) Vol. 17, Iss. 4, pp. 706-706
Open Access
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová
Vnitřní lékařství (2025) Vol. 71, Iss. 1, pp. 51-57
Closed Access
Adipositastherapie und Diabetesprävention mit Tirzepatid
Robin Schürfeld
Deleted Journal (2025)
Closed Access
Therapie-Update bei Adipositas
Baptist Gallwitz
Info Diabetologie (2025) Vol. 19, Iss. 1, pp. 29-36
Closed Access
November Industry News
Fiona McCartney
Therapeutic Delivery (2025), pp. 1-6
Closed Access
Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
Emily R. Hankosky, Chanadda Chinthammit, Alexandra Meeks, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
JCL ROUNDTABLE: PREDIABETES
Kevin C. Maki, Carol F. Kirkpatrick, Jaime P. Almandoz
Journal of clinical lipidology (2025)
Closed Access
Page 1 - Next Page

Scroll to top